Empowered Funds LLC acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 118,890 shares of the company's stock, valued at approximately $2,002,000. Empowered Funds LLC owned about 0.06% of Cellebrite DI as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. MQS Management LLC acquired a new position in shares of Cellebrite DI in the third quarter valued at approximately $294,000. Venturi Wealth Management LLC raised its stake in shares of Cellebrite DI by 28.6% during the third quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company's stock valued at $152,000 after acquiring an additional 2,000 shares during the last quarter. Meritage Portfolio Management lifted its holdings in shares of Cellebrite DI by 12.0% during the third quarter. Meritage Portfolio Management now owns 27,831 shares of the company's stock worth $469,000 after purchasing an additional 2,973 shares during the period. Principal Financial Group Inc. bought a new stake in shares of Cellebrite DI in the third quarter worth $23,402,000. Finally, Harbor Capital Advisors Inc. increased its holdings in Cellebrite DI by 96.1% in the third quarter. Harbor Capital Advisors Inc. now owns 95,351 shares of the company's stock valued at $1,606,000 after purchasing an additional 46,727 shares during the period. Institutional investors and hedge funds own 45.88% of the company's stock.
Analyst Ratings Changes
Several research analysts have commented on CLBT shares. Lake Street Capital lifted their target price on Cellebrite DI from $13.50 to $17.00 and gave the stock a "buy" rating in a report on Friday, August 16th. Bank of America upped their target price on Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 16th. Craig Hallum boosted their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on shares of Cellebrite DI from $21.00 to $22.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Finally, Needham & Company LLC increased their price target on Cellebrite DI from $17.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI currently has an average rating of "Buy" and a consensus price target of $20.29.
View Our Latest Research Report on Cellebrite DI
Cellebrite DI Stock Performance
Shares of Cellebrite DI stock opened at $19.00 on Thursday. The stock's 50-day simple moving average is $17.81 and its 200 day simple moving average is $14.70. Cellebrite DI Ltd. has a 52-week low of $7.91 and a 52-week high of $21.00.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. The business had revenue of $106.90 million for the quarter, compared to analysts' expectations of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business's revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.09 EPS. On average, sell-side analysts predict that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
